The COX-2 Specific Inhibitor, Valdecoxib, Is An Effective, Opioid-Sparing Analgesic in Patients Undergoing Total Knee Arthroplasty Lowell W Reynolds,

Slides:

Advertisements

Similar presentations

Using a Morphine Equivalence Metric to Quantify Opioid Consumption: Examining the Capacity to Provide Effective Treatment of Debilitating Pain at the Global,

Advertisements

Capturing the Costs of End-of-Life Care: Comparisons of Multiple Sclerosis, Parkinson's Disease, and Dementia Paul McCrone, PhD Journal of Pain and.

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

The Use of Exparel (Liposomal Bupivacaine) to Manage Postoperative Pain in Unilateral Total Knee Arthroplasty Patients Jonathan W. Surdam, MD, David.

Clinical Trial Results with OROS® Hydromorphone

Winston C. -V. Parris, MD, Benjamin W. Johnson, MD, Marilyn K

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO

Pedal bypass versus tibial bypass with autogenous vein: A comparison of outcome and hemodynamic results Joseph R. Schneider, MD, PhD, Daniel B. Walsh,

The Impact of Chronic Pain on Life in the Household

Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain Jacques R. Caldwell, MD, Ronald J. Rapoport,

Pain, Fatigue, and Sleep Disturbances in Oncology Outpatients Receiving Radiation Therapy for Bone Metastasis Christine Miaskowski, RN, PhD, FAAN, Kathryn.

David M. Simpson, MD, Lydia Estanislao, MD, Stephen J

Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine Rainer Sabatowski, MD, Stefan.

Establishing Mild, Moderate, and Severe Scores for Cancer-Related Symptoms: How Consistent and Clinically Meaningful Are Interference-Based Severity Cut-Points?

Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients Laura L Adams, PhD, Robert.

Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over a Range of Cut-Off Points: Making Clinical Trial Data More Understandable

Midazolam as Adjunct Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced Cancer Alfredo H. Navigante, MD, PhD,

Combination Analgesic Efficacy

The Safety and Efficacy of a Single Dose (500 mg or 1 g) of Intravenous Magnesium Sulfate in Neuropathic Pain Poorly Responsive to Strong Opioid Analgesics.

Rectal and parenteral paracetamol, and paracetamol in combination with NSAIDs, for postoperative analgesia J. Rømsing, S. Møiniche, J.B. Dahl British.

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

Symptomatic Therapy of Dyspnea with Strong Opioids and Its Effect on Ventilation in Palliative Care Patients Katri Elina Clemens, MD, PhD, Eberhard Klaschik,

Antiemetic and analgesic-sparing effects of diphenhydramine added to morphine intravenous patient-controlled analgesia T.-F. Lin, Y.-C. Yeh, Y.-H. Yen,

Eduardo Bruera, MD, Raul Sala, MD, Odette Spruyt, MD, J

Capturing the Costs of End-of-Life Care: Comparisons of Multiple Sclerosis, Parkinson's Disease, and Dementia Paul McCrone, PhD Journal of Pain and.

Double-Blind, Placebo-Controlled Trial of Lamotrigine in Combination with Other Medications for Neuropathic Pain Marianne Silver, MS, David Blum, MD,

Benefit of Early Palliative Care Intervention in End-Stage Liver Disease Patients Awaiting Liver Transplantation Alexandra J. Baumann, DO, David S. Wheeler,

David M. Dosa, MD, MPH, David D

Bruce H. Chamberlain, MD, Karen Cross, MD, Jaron L

Morphine with Dextromethorphan

Gastrointestinal Effects of NSAIDs and Coxibs

Fentanyl-Induced Neurotoxicity and Paradoxic Pain

Advances in Rheumatology

Transdermal Fentanyl for Chronic Pain in AIDS

Life-Sustaining Treatment Preferences: Matches and Mismatches Between Patients' Preferences and Clinicians' Perceptions Lois Downey, MA, David H. Au,

Redefining Appropriate Treatment Expectations

Clinical Response to an Outpatient Palliative Care Consultation in Patients With Advanced Cancer and Cancer Pain Sriram Yennurajalingam, MD, Jung Hun.

Treatment of Cancer Pain with Noninvasive Brain Stimulation

Changes in Symptom Intensity Among Cancer Patients Receiving Outpatient Palliative Care Jung Hun Kang, MD, PhD, Jung Hye Kwon, MD, PhD, David Hui, MD,

Characterization of the early pharmacodynamic profile of oral methadone for cancer- related breakthrough pain: a pilot study Kim Fisher, PhD, Carla Stiles,

Suresh K Joishy, MD, FACP, Declan Walsh, MSc, FACP

Paul A. Sloan, MD, Dwight E. Moulin, MD, FRCP(C), Helen Hays, MD

A Pilot Exploration of the Antiemetic Activity of Olanzapine for the Relief of Nausea in Patients with Advanced Cancer and Pain Steven D. Passik, PhD,

Symptom Prevalence and Management of Cancer Patients in Lebanon

The Role of Patients' Expectations in the Development of Anticipatory Nausea Related to Chemotherapy for Cancer Jane T. Hickok, MD, MPH, Joseph A. Roscoe,

Abuse Potential of Morphine/Dextromethorphan Combinations

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

Intrathecal sufentanil and morphine for post-thoracotomy pain relief†

Strategies in Pain Management

Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain

Methadone Analgesia in Cancer Pain Patients on Chronic Methadone Maintenance Therapy Paolo L Manfredi, MD, Gilbert R Gonzales, Andrea L Cheville, Craig.

Improving Access to Opioid Analgesics for Palliative Care in India

Changing M3G/M6G Ratios and Pharmacodynamics in a Cancer Patient During Long- Term Morphine Treatment Gertrud Andersen, MD, Lona L Christrup, PhD, Per.

Proglumide as a Morphine Adjunct in Cancer Pain Management

Blinded Patient Preference for Morphine Compared to Placebo in the Setting of Chronic Refractory Breathlessness—An Exploratory Study Diana H. Ferreira,

The Spiritual Needs Assessment for Patients (SNAP): Development and Validation of a Comprehensive Instrument to Assess Unmet Spiritual Needs Rashmi K.

Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial Elyse E. Lower, MD, Atul Malhotra, MD, Victoria Surdulescu,

Intravenous acetaminophen analgesia after cardiac surgery: A randomized, blinded, controlled superiority trial Negmeldeen F. Mamoun, MD, PhD, Peirong.

Gertrud Andersen, MD, Lona Christrup, PhD, Per Sjøgren, MD

The impact of demographic and disease-specific variables on pain in cancer patients Tone Rustøen, RN, PhD, Sophie D Fosså, MD, Dr Med Sci, Jon Skarstein,

A Scale for Measuring Patient Perceptions of the Quality of End-of-Life Care and Satisfaction with Treatment Daniel P. Sulmasy, OFM, MD, PhD, Jessica.

Knowledge and Attitudes of Italian Medical Staff Towards the Approach and Treatment of Patients in Pain Marco Visentin, MD, Leonardo Trentin, MD, Roberto.

Michael W. Payne, MSc, Robert J. Petrella, MD, PhD

A Titrated Morphine Analgesic Regimen Comparing Substance Users and Non-Users with AIDS-Related Pain Ronald Kaplan, MD, Joseph Slywka, PhD, Susan Slagle,

Physical Function in Patients with Cancer

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery Elisabeth Ott,

Nathaniel P Katz, MD Journal of Pain and Symptom Management

Pain Management, Controlled Substances, and State Medical Board Policy

Comparative clinical effects of hydromorphone and morphine: a meta-analysis L. Felden, C. Walter, S. Harder, R.-D. Treede, H. Kayser, D. Drover, G. Geisslinger,

Nausea and Vomiting Remain a Significant Clinical Problem

Presentation transcript:

The COX-2 Specific Inhibitor, Valdecoxib, Is An Effective, Opioid-Sparing Analgesic in Patients Undergoing Total Knee Arthroplasty Lowell W Reynolds, MD, Robert K Hoo, MD, Robert J Brill, MD, Janine North, MS, David P Recker, MD, Kenneth M Verburg, PhD Journal of Pain and Symptom Management Volume 25, Issue 2, Pages 133-141 (February 2003) DOI: 10.1016/S0885-3924(02)00637-1

Fig. 1 Cumulative amount of morphine consumed over 48 hours (mean ± SEM: standard error of the mean). Patients receiving valdecoxib 40 mg bid consumed statistically significantly less morphine compared with those patients receiving morphine alone from 24 hours till the end of the study period *P < 0.05. Journal of Pain and Symptom Management 2003 25, 133-141DOI: (10.1016/S0885-3924(02)00637-1)

Fig. 2 Pain Intensity Difference Categorical Scale (Mean ± SEM) over 48 hours. Pain intensity at time specific intervals was lower in the valdecoxib 20 mg bid and valdecoxib 40 mg bid treatment groups compared with morphine plus placebo. These differences were significant from 12–48 hours for valdecoxib 40 mg bid and for valdecoxib 20 mg bid at 18, 24 and 36 hours *P < 0.05. PID scores were derived by subtracting the pain intensity score at each time point from the baseline pain intensity score. A higher positive score indicates greater pain relief, whereas a negative score indicates increased pain intensity from baseline. Journal of Pain and Symptom Management 2003 25, 133-141DOI: (10.1016/S0885-3924(02)00637-1)